The Breast International Group, the European Organization for Research and Treatment of Cancer and the Alliance Foundation Trials groups are collaborating with Sanofi to initiate a pivotal trial of an oral selective estrogen receptor degrader (SERD) in the adjuvant setting.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe